Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Shire
Information provided by (Responsible Party):
Shire Identifier:
First received: January 30, 2014
Last updated: July 8, 2016
Last verified: July 2016

Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent angioedema attacks in children 6 to 11 years of age with hereditary angioedema (HAE).

Secondary Objectives - To assess the safety and tolerability, characterize the pharmacokinetics (PK) and pharmacodynamics (PD), and assess the immunogenicity of two dose levels of CINRYZE administered by IV injection in children 6 to 11 years of age with HAE.

Condition Intervention Phase
Hereditary Angioedema (HAE)
Biological: CINRYZE 500
Biological: CINRYZE 1000
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Number of angioedema attacks in each treatment period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of subjects with adverse events by dose group [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in C1 inhibitor (C1 INH) and C4 concentrations during each treatment period [ Time Frame: Pre-dose to 1 hour post-dose at Visit 1, Week 6, and Week 12 ] [ Designated as safety issue: No ]
  • Number of subjects with C1 INH antibodies [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 12
Study Start Date: February 2014
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 500/1000
500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
Biological: CINRYZE 500
500 Units of CINRYZE administered by IV injection
Biological: CINRYZE 1000
1000 Units of CINRYZE administered by IV injection
Experimental: 1000/500
1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
Biological: CINRYZE 500
500 Units of CINRYZE administered by IV injection
Biological: CINRYZE 1000
1000 Units of CINRYZE administered by IV injection


Ages Eligible for Study:   6 Years to 11 Years   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Type I or Type II HAE.
  • History of angioedema attacks.

Exclusion Criteria:

  • History of bleeding or clotting abnormality.
  • Diagnosis of acquired angioedema or known to have C1 INH antibodies.
  • History of allergic reaction to C1 esterase inhibitor or other blood products.
  • Receipt of any experimental agents other than those required for prevention or treatment of angioedema attacks within 30 days prior to screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02052141

Contact: Shire Contact +1 866 842 5335

United States, California
Santa Monica Clinical Trials Withdrawn
Santa Monica, California, United States, 90404
United States, Colorado
Asthma and Allergy Associates, P.C Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Krystal Payton    719-473-8330 ext 3      
United States, Nevada
Nevada Access to Research and Education Society Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Joanne Petruso    702-384-9101      
United States, Oregon
Oregon Allergy Associates Recruiting
Eugene, Oregon, United States, 97401
Contact: Melanie Wayne, RN, BSN    541-431-9437      
Klinikum der J.W. Goethe Universitat Recruiting
Frankfurt, Germany, 60590
Contact: Alexandra Thalhammer    +496963016312      
HZRM Hamophilie Zentrum Rhein Main GmbH Recruiting
Mörfelden-Walldorf, Germany, 64546
Contact: Zeynep Gutowski    +49 (0) 6105-96389-54      
Tel Aviv Sourasky Medical Center, Pulmonology and Allergy Unit Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Dania Dror    (972)36973591   
Sheba Medical Center Allergy and Immunology Angioedema Center Not yet recruiting
Tel Hashomer, Israel, 52621
Contact: Iris Leibovich    (972)3530530837   
Investigative Site Withdrawn
Salerno, Italy, 84131
Instituto Nacional de Pediatria Recruiting
Mexico City, Mexico, 04530
Contact: Sandra Nieto    +52(55)56063489   
Clinical County Hospital Mures Recruiting
Targu-Mures, Romania, 540072
Contact: Dumitru Moldovan, MD   
United Kingdom
Royal Manchester Children's Hospital Recruiting
Manchester, United Kingdom, M13 9WL
Contact: Natalie Plimmer    +44 161 701 1910      
Sponsors and Collaborators
Study Director: Jennifer Schranz, MD Shire
  More Information

Responsible Party: Shire Identifier: NCT02052141     History of Changes
Other Study ID Numbers: 0624-301  2013-002453-29  SHP616-301 
Study First Received: January 30, 2014
Last Updated: July 8, 2016
Health Authority: Romania: National Agency for Medicines and Medical Devices
Italy: The Italian Medicines Agency
United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Paul-Ehrlich-Institut
Mexico: Federal Commission for Protection Against Health Risks

Keywords provided by Shire:
C1 inhibitor

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 25, 2016